share_log

Bristol Myers Squibb Announced Topline Data From Its Phase 3 Study Of COBENFY That Showed Continuing Improvement In Symptoms Of Schizophrenia

Benzinga ·  16:19
Bristol Myers Squibb Announced Topline Data From Its Phase 3 Study Of COBENFY That Showed Continuing Improvement In Symptoms Of Schizophrenia
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment